
    
      The study will comprise:

        -  A Screening period of maximum 28 days;

        -  Five treatment periods during which subjects will be resident from the morning on the
           day before dosing with the IMP (Day -1) until at least 48 hours after dosing; discharge
           will be on the morning of Day 3, and

        -  A Follow-up Visit within 7 to 10 days after the last administration of the IMPs.

        -  There will be a minimum of a 7 days washout between each treatment period.

      Each subject will receive 5 treatments. The following treatments will be given:

        -  Treatment A: 10 mg rosuvastatin tablet alone (fasting state)

        -  Treatment B: 10 mg rosuvastatin tablet + 200 mg of AZD5718 IR tablet (2 x 100 mg tablet)
           (fasting state)

        -  Treatment C: 200 mg of AZD5718 IR tablet (2 x 100 mg tablet) (fasting state)

        -  Treatment D: 200 mg of AZD5718 oral suspension 50 mg/mL (fasting state)

        -  Treatment E: 200 mg of AZD5718 IR tablet (2 x 100 mg tablet) (fed state)

      Each subject will be involved in the study for approximately 8 weeks.
    
  